Allogene Therapeutics (ALLO) Equity Average (2018 - 2026)

Allogene Therapeutics has disclosed Equity Average across 9 years of filings, most recently posting $285.7 million for Q1 2026.

• Equity Average for Q1 2026 came in at $285.7 million, down 29.24% year-over-year; the trailing twelve-month figure through Mar 2026 was $285.7 million (down 29.24% YoY), and the FY2025 annual result was $357.4 million, down 23.51% from the prior year.
• Equity Average came in at $285.7 million for Q1 2026 at Allogene Therapeutics, down from $303.9 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $895.2 million in Q1 2022 to a low of $285.7 million in Q1 2026.
• The 5-year median for Equity Average is $489.4 million (2024), against an average of $540.6 million.
• Across the five-year window, Equity Average slipped 14.05% in 2022 and plunged 32.58% in 2025, its largest moves.
• Allogene Therapeutics' Equity Average stood at $705.1 million in 2022, then retreated by 22.51% to $546.4 million in 2023, then dropped by 18.94% to $443.0 million in 2024, then sank by 31.39% to $303.9 million in 2025, then declined by 6.0% to $285.7 million in 2026.
• The last three Equity Average figures came in at $285.7 million (Q1 2026), $303.9 million (Q4 2025), and $329.9 million (Q3 2025), per Business Quant data.